FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/INCY
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Incyte Corporation (INCY) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Incyte (INCY) trades at $120.04, down 0.29% on the day, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, though 2026 projections show lower profitability. Recent FDA approval for Atebrioz and expanded partnerships support growth beyond its key drug JAKAFI, as the company targets $4B in non-JAKAFI sales.
The outlook is cautiously optimistic, with a consensus price target of $137.67 offering 15% upside. Risks include JAKAFI's patent expiration after 2029 and volatile earnings, but strong cash flow and a diversified pipeline provide a foundation for long-term value. Analyst sentiment is positive with 53% buy ratings, though high P/E of 61.26 warrants valuation scrutiny.
Read full analysis

Key Stats

  • Market Cap
    $24.47B
  • Volume
    1,748,032
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $90.30
  • Typical Hold Time
    34 Days
  • Enterprise Value
    $20.65B
  • Div Yield
    -
  • Trading Activity
    -
$117.31
52W Low: $90.3
27 Mar 2026
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $90.3 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Most Recent News

Content is generated by Aura AI

Nova Klúbburinn completes share buyback, purchasing 122.7 million shares at ISK 3.26 each

Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...

Market News
4 hours ago
Na
Neutral
Nova Klúbburinn completes share buyback, purchasing 122.7 million shares at ISK 3.26 each

This overlooked ETF outperforms Vanguard's international dividend fund over 5 and 10 years.

The ALPS International Sector Dividend Dogs ETF (IDOG), a smaller and less known fund, has outperformed the popular Vanguard International High Dividend Yield ETF (VYMI) over five and ten years by focusing on high-yielding stocks equally weighted acr...

Market News
5 hours ago
24/7 Wall Street
Bullish
news icon
This overlooked ETF outperforms Vanguard's international dividend fund over 5 and 10 years.

Bio-Techne declares $0.08 quarterly dividend, pending Merck acquisition closure by Nov 13, 2026.

Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the period ending September 30, 2026, payable on November 23, 2026. This dividend will be paid only if the company's acquisition by Merck KGaA has not closed by November 13,...

Company Fundamentals
5 hours ago
PRNewsWire
Neutral
Bio-Techne declares $0.08 quarterly dividend, pending Merck acquisition closure by Nov 13, 2026.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $24.47B
  • Volume
    1,748,032
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $90.30
  • Typical Hold Time
    34 Days
  • Enterprise Value
    $20.65B
  • Div Yield
    -
  • Trading Activity
    -
$117.31
52W Low: $90.3
27 Mar 2026
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $90.3 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!